Vistin Pharma ASA: Fourth quarter 2019 financial results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Oslo, Norway, 28 February 2020Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter of 2019, with a 40% increase in revenue and robust earnings in the pharmaceutical business unit and unrealised gains on oil derivatives of NOK 0.6 million.The revenues for the fourth quarter 2019 ended at NOK 56.8 million (Q4 2018: NOK 40.6 million).The net profit ended at NOK 4.2 million (-64.0) in the fourth quarter of 2019, which included an unrealised financial gain on oil derivatives portfolio of NOK 0.6 million (-65.2) for the period.Vistin Pharma had cash of NOK 319.6 million (320.7) as of 31 December 2019.The fourth quarter conference call, which will be held today, 28 February, at 8.30am (CEST) and will be available via web and audio through the following access points:Telephone conference:
Confirmation Code:…….. 6394327
International Dial-In:…….. +44 (0) 2071 928000
Norway, Oslo:……………. +47 23960264
United States, New York: +16315107495Webcast:
https://edge.media-server.com/mmc/p/zxt9i6wnThe conference call will be held in Norwegian.
       Please find the Q4 2019 Report and presentation enclosed. The report will also be made available on www.vistin.com.*****For further information, please contact:
Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Vistin Pharma | www.vistin.comVistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.AttachmentsVistin Pharma ASA fourth quarter presentation 2019Vistin Pharma ASA fourth quarter report 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.